Trial · NCT06733935
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NCT06733935, Phase 1, Phase 2, Recruiting, Nkarta, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2). Trials, record NCT06733935. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06733935
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- NCT number
- NCT06733935
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 240 participants, estimated
- Lead sponsor
- Nkarta, Inc.
- Conditions
- Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
- Interventions
- NKX019, Fludarabine, Cyclophosphamide
- First posted
- 2024-12-13
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes47
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Dose-limiting toxicities (DLTs) [Safety and Tolerability] | The first 28 days after the first NKX019 dose | Incidence of DLTs will be evaluated |
| Primary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | From the first administration of NKX019 until the last administration of any study treatment + 30 days | Incidence and severity of treatment-emergent adverse events will be evaluated |
| Secondary | For all participants with Interstitial Lung Disease (ILD) | Up to 2 years after NKX019 infusion | Change from baseline in % predicted forced vital capacity (FVC) over time |
| Secondary | For all participants with Interstitial Lung Disease (ILD) | Up to 2 years after NKX019 infusion | Change from baseline in FVC volume over time |
| Secondary | For all participants with Interstitial Lung Disease (ILD) | Up to 2 years after NKX019 infusion | Change from baseline % predicted diffusing capacity of the lung for carbon monoxide (DLCO) corrected for hemoglobin \[and as appropriate alveolar volume (AV)\] over time |
| Secondary | For all participants with Interstitial Lung Disease (ILD) | Up to 2 years after NKX019 infusion | Time to improvement in FVC by ≥5% or ≥10% |
| Secondary | For all participants with Interstitial Lung Disease (ILD) | Up to 2 years after NKX019 infusion | Proportion of participants with improvement in FVC by ≥5% or ≥10% |
| Secondary | For all participants with Interstitial Lung Disease (ILD) | Up to 2 years after NKX019 infusion | Time to ILD progression |
| Secondary | For all participants with Interstitial Lung Disease (ILD) | Up to 2 years after NKX019 infusion | Proportion of participants with ILD progression |
| Secondary | For all participants with Systemic Sclerosis (SSc) | Up to 2 years after NKX019 infusion | Change from baseline in modified Rodnan skin score (mRSS) |
1 to 10 of 47Source ClinicalTrials.gov
See all 47 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06733935
GET https://conductscience.org/api/trials/v1/NCT06733935/registered?page=2